Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Depreciation and Depletion (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Depreciation and Depletion for 6 consecutive years, with $59945.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 0.67% year-over-year to $59945.0, compared with a TTM value of $239760.0 through Dec 2025, up 3.82%, and an annual FY2025 reading of $239363.0, up 6.63% over the prior year.
  • Depreciation and Depletion was $59945.0 for Q4 2025 at Neuroone Medical Technologies, up from $58745.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $61015.0 in Q2 2025 and bottomed at $13715.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $42115.8, with a median of $52229.0 recorded in 2023.
  • The sharpest move saw Depreciation and Depletion skyrocketed 104.47% in 2023, then increased 0.34% in 2025.
  • Year by year, Depreciation and Depletion stood at $19582.0 in 2021, then surged by 54.79% to $30310.0 in 2022, then surged by 75.12% to $53078.0 in 2023, then grew by 12.19% to $59548.0 in 2024, then rose by 0.67% to $59945.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for NMTC at $59945.0 in Q4 2025, $58745.0 in Q3 2025, and $61015.0 in Q2 2025.